Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib, Pembrolizumab, and Carboplatin in 1L R/M HNSCC
NCT04643379Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2021
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in head and neck squamous cell carcinoma (HNSCC), sponsored by Washington University School of Medicine. Started Aug 2021; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04643379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04643379.